{"entity":{"type":"insider","cik":"0001883821","url":"/insider/0001883821","json_url":"/insider/0001883821.json","name":"Haas Jason","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":8,"n_filings":5,"first":"2024-09-12","last":"2026-08-14","span_basis":"filed_date"},"name_variants":[{"name":"Haas Jason","source":"filing","n_filings":5,"first_seen":"2024-09-12","last_seen":"2026-08-14"}],"transactions":[{"id":9296999,"accession":"0002001011-26-000114","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0002001011-26-000114","line_url":"/filing/0002001011-26-000114#line-1","is_derivative":false,"issuer_cik":"0000886163","issuer_name":"LIGAND PHARMACEUTICALS INC","issuer_ticker":"LGND","issuer_name_source":null,"issuer_url":"/issuer/0000886163","owner_cik":"0001883821","owner_name":"Haas Jason","owner_display_name":"Haas Jason","owner_url":"/insider/0001883821","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7138.0,"shares_display":"7,138","price_per_share":292.8078,"price_display":"292.81","price_state":"stated","total_value":2090062.0764,"total_display":"2,090,062.08","total_whole":"2,090,062","shares_owned_after":3981.0,"shares_owned_after_display":"3,981","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-12","filed_date":"2026-08-14","scope":"insider"},{"id":5902826,"accession":"0002001011-26-000104","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0002001011-26-000104","line_url":"/filing/0002001011-26-000104","is_derivative":false,"issuer_cik":"0000886163","issuer_name":"LIGAND PHARMACEUTICALS INC","issuer_ticker":"LGND","issuer_name_source":null,"issuer_url":"/issuer/0000886163","owner_cik":"0001883821","owner_name":"Haas Jason","owner_display_name":"Haas Jason","owner_url":"/insider/0001883821","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6461.0,"shares_display":"6,461","price_per_share":255.58275872156014,"price_display":"255.58","price_state":"stated","total_value":1651320.2041,"total_display":"1,651,320.20","total_whole":"1,651,320","shares_owned_after":4981.0,"shares_owned_after_display":"4,981","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-12","filed_date":"2026-06-15","scope":"insider","n_lines":2},{"id":5797823,"accession":"0001193125-26-217600","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-217600","line_url":"/filing/0001193125-26-217600#line-1","is_derivative":false,"issuer_cik":"0001882782","issuer_name":"Odyssey Therapeutics, Inc.","issuer_ticker":"ODTX","issuer_name_source":null,"issuer_url":"/issuer/0001882782","owner_cik":"0001883821","owner_name":"Haas Jason","owner_display_name":"Haas Jason","owner_url":"/insider/0001883821","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":20000.0,"total_display":"20,000.00","total_whole":"20,000","shares_owned_after":62908.0,"shares_owned_after_display":"62,908","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-08","filed_date":"2026-05-11","scope":"insider"},{"id":2125629,"accession":"0000950170-24-129378","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-129378","line_url":"/filing/0000950170-24-129378#line-1","is_derivative":false,"issuer_cik":"0001556263","issuer_name":"Syros Pharmaceuticals, Inc.","issuer_ticker":"SYRS","issuer_name_source":null,"issuer_url":"/issuer/0001556263","owner_cik":"0001883821","owner_name":"Haas Jason","owner_display_name":"Haas Jason","owner_url":"/insider/0001883821","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":137803.0,"shares_display":"137,803","price_per_share":0.2103,"price_display":"0.21","price_state":"stated","total_value":28979.9709,"total_display":"28,979.97","total_whole":"28,980","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-18","filed_date":"2024-11-20","scope":"insider"},{"id":2461787,"accession":"0000950170-24-105995","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-105995","line_url":"/filing/0000950170-24-105995#line-3","is_derivative":false,"issuer_cik":"0001556263","issuer_name":"Syros Pharmaceuticals, Inc.","issuer_ticker":"SYRS","issuer_name_source":null,"issuer_url":"/issuer/0001556263","owner_cik":"0001883821","owner_name":"Haas Jason","owner_display_name":"Haas Jason","owner_url":"/insider/0001883821","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":45344.0,"shares_display":"45,344","price_per_share":1.6762,"price_display":"1.68","price_state":"stated","total_value":76005.6128,"total_display":"76,005.61","total_whole":"76,006","shares_owned_after":124552.0,"shares_owned_after_display":"124,552","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-12","filed_date":"2024-09-12","scope":"insider"},{"id":2461780,"accession":"0000950170-24-105995","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-105995","line_url":"/filing/0000950170-24-105995#line-2","is_derivative":false,"issuer_cik":"0001556263","issuer_name":"Syros Pharmaceuticals, Inc.","issuer_ticker":"SYRS","issuer_name_source":null,"issuer_url":"/issuer/0001556263","owner_cik":"0001883821","owner_name":"Haas Jason","owner_display_name":"Haas Jason","owner_url":"/insider/0001883821","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":19293.0,"shares_display":"19,293","price_per_share":1.5781,"price_display":"1.58","price_state":"stated","total_value":30446.2833,"total_display":"30,446.28","total_whole":"30,446","shares_owned_after":79208.0,"shares_owned_after_display":"79,208","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-11","filed_date":"2024-09-12","scope":"insider"},{"id":2461777,"accession":"0000950170-24-105995","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-105995","line_url":"/filing/0000950170-24-105995#line-1","is_derivative":false,"issuer_cik":"0001556263","issuer_name":"Syros Pharmaceuticals, Inc.","issuer_ticker":"SYRS","issuer_name_source":null,"issuer_url":"/issuer/0001556263","owner_cik":"0001883821","owner_name":"Haas Jason","owner_display_name":"Haas Jason","owner_url":"/insider/0001883821","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":35363.0,"shares_display":"35,363","price_per_share":1.5493,"price_display":"1.55","price_state":"stated","total_value":54787.8959,"total_display":"54,787.90","total_whole":"54,788","shares_owned_after":59915.0,"shares_owned_after_display":"59,915","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-10","filed_date":"2024-09-12","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":8,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":4,"open_market":true},{"code":"S","label":"Open-market sale","n":4,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":8},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000886163","name":"LIGAND PHARMACEUTICALS INC","url":"/issuer/0000886163","role":"Director","n_filings":2,"first_seen":"2026-06-15","last_seen":"2026-08-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001882782","name":"Odyssey Therapeutics, Inc.","url":"/issuer/0001882782","role":"Officer (Chief Financial Officer)","n_filings":1,"first_seen":"2026-05-11","last_seen":"2026-05-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001556263","name":"Syros Pharmaceuticals, Inc.","url":"/issuer/0001556263","role":"Officer (Chief Financial Officer)","n_filings":2,"first_seen":"2024-09-12","last_seen":"2024-11-20"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001883821","retrieved_at":"2026-08-27T18:10:43+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}